A phase II/III, observer-blind, randomised, active controlled study to compare the safety and immunogenicity of a meningococcal A conjugate vaccine (PsA-TT) with meningococcal ACWY polysaccharide vaccine administered in healthy subjects 2 to 29 years of age
Latest Information Update: 30 Nov 2020
At a glance
- Drugs Meningococcal vaccine group A conjugate (Primary) ; Meningococcal vaccine groups A C Y W-135 polysaccharide
- Indications Bacterial meningitis; Meningococcal group A infections; Meningococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Serum Institute of India
- 19 Nov 2020 Results of secondary analysis from four clinical studies: PsATT-002, PsATT-003, PsATT-004 and PsATT-007 assessing safety and efficacy in children in African meningitis belt published in the Vaccine
- 15 Nov 2015 Results published in the Clinical Infectious Diseases
- 16 Jun 2011 Primary endpoint 'Seroconversion-rate' has been met.